As of 2025-07-19, the EV/EBITDA ratio of Theravance Biopharma Inc (TBPH) is -12.16. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TBPH's latest enterprise value is 482.86 mil USD. TBPH's TTM EBITDA according to its financial statements is -39.69 mil USD. Dividing these 2 quantities gives us the above TBPH EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.3x - 7.9x | 6.0x |
| Forward P/E multiples | 5.0x - 7.4x | 6.2x |
| Fair Price | (2.58) - (4.28) | (3.25) |
| Upside | -123.0% - -138.1% | -128.9% |
| Date | EV/EBITDA |
| 2025-07-16 | -12.67 |
| 2025-07-15 | -12.52 |
| 2025-07-14 | -12.44 |
| 2025-07-11 | -12.23 |
| 2025-07-10 | -12.43 |
| 2025-07-09 | -12.59 |
| 2025-07-08 | -12.13 |
| 2025-07-07 | -12.24 |
| 2025-07-03 | -12.04 |
| 2025-07-02 | -11.91 |
| 2025-07-01 | -11.74 |
| 2025-06-30 | -11.89 |
| 2025-06-27 | -12.13 |
| 2025-06-26 | -11.51 |
| 2025-06-25 | -11.32 |
| 2025-06-24 | -11.43 |
| 2025-06-23 | -11.31 |
| 2025-06-20 | -11.38 |
| 2025-06-18 | -11.37 |
| 2025-06-17 | -11.35 |
| 2025-06-16 | -11.54 |
| 2025-06-13 | -11.46 |
| 2025-06-12 | -11.36 |
| 2025-06-11 | -11.36 |
| 2025-06-10 | -11.51 |
| 2025-06-09 | -11.79 |
| 2025-06-06 | -12.16 |
| 2025-06-05 | -11.56 |
| 2025-06-04 | -11.86 |
| 2025-06-03 | -12.00 |
| 2025-06-02 | -12.04 |
| 2025-05-30 | -9.53 |
| 2025-05-29 | -9.71 |
| 2025-05-28 | -9.52 |
| 2025-05-27 | -9.68 |
| 2025-05-23 | -9.71 |
| 2025-05-22 | -9.95 |
| 2025-05-21 | -9.85 |
| 2025-05-20 | -9.90 |
| 2025-05-19 | -9.82 |
| 2025-05-16 | -9.58 |
| 2025-05-15 | -9.51 |
| 2025-05-14 | -8.59 |
| 2025-05-13 | -9.22 |
| 2025-05-12 | -9.08 |
| 2025-05-09 | -9.31 |
| 2025-05-08 | -10.46 |
| 2025-05-07 | -10.58 |
| 2025-05-06 | -10.70 |
| 2025-05-05 | -10.96 |